All
Drug Duo Granted Breakthrough Status to Treat Endometrial Cancer
August 2nd 2018The FDA has granted a breakthrough therapy designation to the combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after at least one prior systemic therapy.
Transitioning From Patient to Survivor
July 31st 2018You are one person before the diagnosis comes, you are another person during the journey and you are different person when remission is gained. That is not to say that certain pieces of you don't remain, but I feel it nearly impossible to go through this journey unchanged.
Two Large Trials Investigate Combination Immunotherapy in Bladder Cancer
July 31st 2018With five immunotherapy drugs approved in the bladder cancer space, the next question researchers find themselves asking is whether these drugs would work better alone or as part of a combination for patients with metastatic disease.
FDA Approves Azedra for Rare Neuroendocrine Tumors
July 31st 2018The Food and Drug Administration (FDA) has approved Azedra (iobenguane I-131) for adult and pediatric patients aged 12 years or older with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy.
Finding Patients Close to Home: A New Way of Recruiting for Clinical Trials
July 30th 2018The speakers noted that certain well-known cancer centers are highly sought by organizations planning trials, due to their success at enrolling participants. That breeds competition among the hosts of trials to work with those centers and enroll their patients, which is detrimental to the pace of research overall.